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Abstract 
Background: Pirfenidone is an anti-fibrotic agent shown to slow the progression of idiopathic pulmonary fibrosis 
(IPF). However, its effectiveness in association with serological autoimmune features in IPF remains unclear.
Methods: We retrospectively reviewed the medical records of patients with IPF treated at a tertiary care hospital in 
South Korea. The autoantibody status was defined as positive if we detected autoantibodies meeting the serological 
domain criteria for interstitial pneumonia with autoimmune features or anti-neutrophil cytoplasmic antibodies.
Results: We included 142 patients with IPF treated with pirfenidone for over six months (93 were autoantibody-
positive and 49 were autoantibody-negative). The mean age was 69.5 ± 7.3 years, and 77.5% of the patients were 
male. The adjusted mean changes over one year were − 34.4 and − 112.2 mL (p = 0.168) in forced vital capacity (FVC), 
and − 0.53 and − 0.72 mL/mmHg/min (p = 0.356) in the lungs diffusion capacity for carbon monoxide  (DLCO) in the 
autoantibody-negative and autoantibody-positive groups, respectively.
Conclusions: Reductions in FVC and  DLCO were similar in autoantibody-positive and autoantibody-negative patients 
with IPF treated with pirfenidone. Pirfenidone is effective in attenuating the progression of IPF, irrespective of the 
autoantibody status.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, and fibrosing interstitial pneumonia of unknown 
cause, characterized by a histopathological pattern 
of usual interstitial pneumonia (UIP) [1]. Exclusion 
of known causes of interstitial pneumonia, including 
environmental exposures, drug toxicities, and connective 
tissue diseases (CTDs), is important for IPF diagnosis 
because it affects the treatment and prognosis [2, 3].
Rheumatoid arthritis, systemic lupus erythematosus, 
idiopathic inflammatory myopathies, Sjögren’s syndrome, 
systemic sclerosis, and mixed connective tissue disease 
are representative CTDs that might involve the lungs and 
cause fibrotic lung disorders. Each CTD has its unique 
clinical features and presents specific autoantibody posi-
tivity that can help to distinguish it from other CTDs. An 
official IPF diagnostic guideline proposed by the Inter-
national Consensus Statement of the American Thoracic 
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Society and European Respiratory Society also recom-
mends serologic autoantibody tests in all patients with 
newly identified interstitial lung disease to exclude CTDs 
[1]. However, CTDs might initially involve only the lungs, 
without extrathoracic features [4]. Furthermore, symp-
toms and signs of extrapulmonary involvement might not 
be present at the time of diagnosis, or they might be sub-
tle [5]. These factors complicate the differential diagnoses 
of fibrotic lung disease.
The term interstitial pneumonia with autoimmune 
features (IPAF) was recently proposed to describe indi-
viduals with interstitial lung disease and other clinical, 
serologic, and morphologic features that presumably 
arise from an underlying autoimmune condition but do 
not meet the current diagnostic criteria for a CTD [6]. 
This group of patients demonstrates better survival than 
patients with IPF but markedly worse survival than those 
with CTD-related interstitial lung disease [7, 8]. The 
diagnostic criteria of IPAF include the clinical, serologic, 
and morphologic domains.
However, UIP is excluded from the morphologic 
domain because its association with CTD is weaker than 
that of the morphologic patterns observed in other dis-
eases, such as non-specific interstitial pneumonia, organ-
izing pneumonia, and lymphoid interstitial pneumonia. 
Therefore, patients with UIP, positive for autoantibod-
ies, who do not meet the diagnostic criteria for CTD, 
are diagnosed with IPF and treated according to the IPF 
guidelines.
Autoantibody positivity has previously been reported 
in 23–41% of patients with IPF [9–13]. To date, little is 
known about the clinical implications of autoantibody 
positivity in IPF, and the reported results are somewhat 
controversial. Some studies reported that autoantibody 
positivity was associated with a better survival outcome 
[10, 12], while others reported no survival difference 
between autoantibody-positive and autoantibody-neg-
ative patients [11, 13]. One retrospective study reported 
that treating autoantibody-positive IPF with immu-
nomodulators was associated with a superior survival 
outcome [12]. However, it is not known if IPF with differ-
ent serological autoimmune presentation respond differ-
ently to the antifibrotic treatment.
This retrospective study aimed to investigate whether 
pirfenidone, an antifibrotic agent currently used to treat 




We retrospectively reviewed the medical records of 
patients with IPF treated at Severance Hospital, a tertiary 
care university hospital in South Korea, between January 
2013 and March 2018. A total of 820 patients of IPF were 
initially screened, and 544 were excluded for the follow-
ing reasons: lost to follow-up or transfer to another hos-
pital (n = 401), underwent lung transplantation (n = 113), 
absence of two or more pulmonary function tests (PFTs) 
separated by at least six months (n = 30). After exclud-
ing those patients, 276 patients were eventually identi-
fied. Of these, 92 were never treated with pirfenidone 
and 184 were treated with pirfenidone, and 142 of them 
treated for more than 6 months. The patient recruitment 
flowchart is presented in Fig. 1. The Institutional Review 
Board and Ethics Committee of Severance Hospital 
approved this study (number: 4-2018-0435). All proce-
dures were performed in accordance with the Declara-
tion of Helsinki. The requirement for written informed 
consent was waived due to the retrospective study design.
Definitions
IPF was diagnosed by a multidisciplinary team of pulmo-
nologists, radiologists, and pathologists specializing in 
chest diseases. The diagnosis was based on the diagnostic 
criteria set by the International Consensus Statement of 
the American Thoracic Society and European Respiratory 
Society in 2011 [14]. The autoantibody status was con-
sidered positive if the serologic test detected any of the 
screened autoantibodies in the IPAF serologic domain [8] 
or anti-neutrophil cytoplasmic antibodies (ANCA).
Serologic autoantibodies analysis
The following serologic autoantibodies were evaluated: 
antinuclear antibody (ANA), rheumatoid factor (RF), 
cyclic citrullinated peptide antibody, anti-dsDNA anti-
body, anti-Ro antibody, anti-La antibody, anti-ribonu-
cleoprotein antibody, anti-Smith antibody, anti-Scl-70 
antibody, anti-Jo-1 antibody, myeloperoxidase, ANCA, 
and proteinase-3 ANCA. ANA positivity with a diffuse, 
homogeneous, or speckled staining pattern and a titer 
cutoff value of 1:320 was required to classify the test as 
positive [15]. ANA was considered positive irrespective 
of the titer if accompanied by either a nucleolar or cen-
tromere staining pattern. Serum RF level greater than or 
equal to twice the normal upper limit was classified as 
positive. We set these minimums because low ANA and 
RF titers are present in some patients without rheumatic 
autoimmune disorders and even healthy individuals [16, 
17]. Other circulating autoantibodies with any value 
above the normal upper limit were considered positive.
Statistical analysis
The forced vital capacity (FVC) and diffusing capacity of 
the lungs for carbon monoxide  (DLCO) were compared 
between baseline and 12  months later using the linear 
mixed model with Bonferroni correction. Corrections for 
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age, sex, height, and weight, all of which affect the FVC, 
were included in the linear mixed model. Continuous 
variables were analyzed by the Student’s t-test and Wil-
coxon signed rank-sum test. Categorical variables were 
analyzed by the Chi-square and Fisher’s exact tests. In 
all cases, differences with a p-value < 0.05 were consid-
ered statistically significant. Statistical analyses were per-
formed using the R statistical software, Version 4.0.0 (R 
Foundation for Statistical Computing, Vienna, Austria).
Results
Patient characteristics
Ninety-two patients who were never treated with 
pirfenidone and 142 patients who received pirfeni-
done for over six months were included in this study 
(Fig.  1; Table  1). Among these 142 patients with IPF, 
the median follow-up period was 24.4  months (inter-
quartile range, 14.9–32.7  months). The mean age was 
69.5 ± 7.3  years, and 77.5% of the patients were male. 
The patients were divided into two groups according 
to their autoantibody status: autoantibody-positive 
(n = 93, 65.5%) and autoantibody-negative (n = 49, 
34.5%). Smoking status, comorbidities, pulmonary 
function, IPF severity represented by the gender–
age–physiology (GAP) index, and the percentage of 
patients experiencing acute IPF exacerbation dur-
ing the study period were similar between the two 
groups. The average pirfenidone dose was also similar 
between the autoantibody-negative and autoantibody-
positive groups (1185.6 and 1183.5  mg, respectively). 
The proportion of patients using systemic corticoster-
oids for over 30  days (38.8% vs. 31.2%, p = 0.470), and 
the duration of use (243.0 [125.0–569.0] days vs. 365.0 
[140.0–649.0] days, p = 0.592) did not show statistically 
significant difference between the autoantibody-posi-
tive group than in the autoantibody-negative group.
There was no difference in the proportion of autoim-
mune positivity according to pirfenidone treatment in 
all patients with IPF (34.5% vs. 38.0%, p = 0.681). The 
predicted values of FVC (77.0 ± 13.0 vs. 83.6 ± 20.0, 
p = 0.006),  FEV1 (90.7 ± 15.0 vs. 96.2 ± 22.6, p = 0.042), 
and  DLCO (63.8 ± 15.8 vs. 70.5 ± 24.4, p = 0.020) in 
patients treated with pirfenidone were significantly lower 
than those of patients who were never treated with pir-
fenidone. This can be explained by the insurance cover-
age criteria in Korea, as the national insurance covered 
IPF patients with PFT result of 50% ≤ FVC ≤ 90% and 
35% ≤ DLco ≤ 80%. Therefore, patients with very good 
pulmonary function (FVC ≥ 90% or DLco ≥ 80%) were 
not treated with pirfenidone.
93 Autoantibody (-)
820 IPF patients
276 patients eventually identified
42 treated for <6 months
184 were treated with 
pirfenidone
401 lost to follow-up, transfer to another 
hospital
113 underwent lung transplantation
30 lacked PFT data
92 were never treated 
with pirfenidone
49 Autoantibody (+)
35 Autoantibody (+) 57 Autoantibody (-)
142 treated with 
Fig. 1 Patient recruitment flow chart. IPF idiopathic pulmonary fibrosis, PFT pulmonary function test
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Table 1 Baseline characteristics of patients
Values are expressed as mean ± standard deviation, number (%) or mean (interquartile range)
BMI body mass index, DLCO diffusing capacity of the lungs for carbon monoxide, FEV1 forced expiratory volume in one second, FVC forced vital capacity, GAP gender, 
age, and physiology, GERD gastroesophageal reflux disease, IPF idiopathic pulmonary fibrosis, IQR Interquartile range, UIP usual interstitial pneumonia
a Computed tomography (CT) scan pattern according to the diagnostic criteria set by the International Consensus Statement of the American Thoracic Society and 
European Respiratory Society in 2011[14]
Patients treated with pirfenidone Patients never treated with pirfenidone
Total (n = 142) Autoantibody ( −) 
(n = 93)
Autoantibody ( +) 
(n = 49)
Total (n = 92) Autoantibody ( −) 
(n = 57)
Autoantibody ( +) 
(n = 35)
Sex (male) 110 (77.5%) 71 (76.3%) 39 (79.6%) 64 (69.6%) 40 (70.2%) 724(68.6%)
Age (year) 69.5 ± 7.3 70.0 ± 6.8 68.5 ± 8.0 67.1 ± 10.3 67.1 ± 11.2 67.0 ± 8.7
BMI (kg/m2) 24.8 ± 2.9 25.2 ± 3.0 24.0 ± 2.7 23.3 ± 3.0 23.2 ± 3.2 23.5 ± 2.6
Smoking exposure (%)
 Never 43 (30.3%) 32 (34.4%) 11 (22.4%) 7 (7.6%) 4 (7.0%) 3 (8.6%)
 Former 80 (56.3%) 50 (53.8%) 30 (61.2%) 51 (55.4%) 34 (59.6%) 17 (48.6%)
 Current 19 (13.4%) 11 (11.8%) 8 (16.3%) 34 (37.0%) 19 (33.3%) 15 (42.9%)
Smoking (pack-
years)
20.0 (0.0–40.0) 20.0 (0.0–36.0) 30.0 (6.0–45.0) 15.0 (0.0–32.5) 20.0 (0.0–35.0) 4.2 (0.0–30.0)
Comorbidities
 Hypertension 30 (21.1%) 23 (24.7%) 7 (14.3%) 44 (47.8%) 28 (49.1%) 16 (45.7%)
 Diabetes mellitus 38 (26.8%) 30 (32.3%) 8 (16.3%) 24 (26.1%) 19 (33.3%) 5 (14.3%)
 GERD 46 (32.4%) 30 (32.3%) 16 (32.7%) 27 (29.3%) 19 (33.3%) 8 (22.9%)
 Asthma 11 (7.7%) 9 (9.7%) 2 (4.1%) 5 (5.4%) 3 (5.3%) 2 (5.7%)
 Old pulmonary 
tuberculosis
28 (19.7%) 19 (20.4%) 9 (18.4%) 18 (19.6%) 13 (22.8%) 5 (14.3%)
 Cancer 29 (20.4%) 18 (19.4%) 11 (22.4%) 23 (25.0%) 17 (29.8%) 6 (17.1%)
 Coronary artery 
disease
25 (19.6%) 14 (15.1%) 11 (22.4%) 19 (20.7%) 11 (19.3%) 8 (22.9%)
 Cerebrovascular 
disease
4 (2.8%) 4 (4.3%) 0 (0.0%) 5 (5.4%) 5 (8.8%) 0 (0.0%)
Pulmonary function test (at IPF diagnosis)
 FVC (L) 2.6 ± 0.7 2.7 ± 0.7 2.6 ± 0.6 2.8 ± 0.9 2.8 ± 0.9 2.8 ± 0.8
 FVC % pred 77.0 ± 13.0 78.2 ± 13.9 74.7 ± 10.8 83.6 ± 20.0 81.8 ± 20.6 86.5 ± 18.8
  FEV1 (L) 2.1 ± 0.5 2.1 ± 0.5 2.1 ± 0.4 2.2 ± 0.7 2.2 ± 0.7 2.2 ± 0.6
  FEV1% pred 90.7 ± 15.0 91.5 ± 14.8 89.3 ± 15.4 96.2 ± 22.6 94.5 ± 23.5 99.1 ± 21.1
  DLCO (mL/mmHg/
min)
10.8 (8.7–13.2) 11.1 (8.7–13.6) 9.8 (8.6–12.0) 13.0 ± 4.6 13.4 ± 4.6 12.2 ± 4.5
  DLCO % pred 63.0 (53.0–73.0) 65.0 (55.0–76.0) 60.0 (52.0–72.0) 70.5 ± 24.4 72.9 ± 25.9 66.7 ± 21.6
Obstructive pattern 8 (5.6%) 5 (5.4%) 3 (6.1%) 7 (7.6%) 5 (8.8%) 2 (5.7%)
Severity of IPF (GAP index)
 I 126 (88.7%) 81 (87.1%) 45 (91.8%) 48 (84.2%) 48 (84.2%) 32 (91.4%)
  II 16 (11.3%) 12 (12.9%) 4 (8.2%) 9 (15.8%) 9 (15.8%) 3 (8.6%)
Follow-up period 
(months)
24.4 (14.9–32.7) 24.4 (16.6–32.2) 24.2 (11.7–32.7) 31.1 (12.6–54.8) 28.7 (13.8–52.7) 40.3 (12.3–56.0)










CT scan  patterna
 UIP 124 (87.3%) 86 (92.5%) 38 (77.6%) 76 (82.6%) 48 (84.2%) 28 (80.0%)
 Possible UIP 18 (12.7%) 7 (7.5%) 11 (22.4%) 16 (17.4%) 9 (15.8%) 7 (20.0%)
UIP by surgical lung 
biopsy
44 (31.0%) 26 (28.0%) 18 (36.7%) 30 (32.6%) 18 (31.6%) 12 (34.3%)
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The positivity rates for the tested autoantibodies are 
presented in Table 2. The highest observed positivity rate 
was for ANA, followed by RF.
Treatment effects
The changes in FVC and  DLCO were compared between 
the autoantibody-positive and autoantibody-nega-
tive patients treated with pirfenidone. These values 
were evaluated after adjusting for sex, age, height, 
weight, and baseline FVC and  DLCO. The adjusted 
mean changes in FVC and  DLCO over one year did not 
differ between the two patient groups (FVC: − 34.4 
vs. − 112.2  mL, p = 0.168;  DLCO: − 0.53 vs. − 0.72  mL/
mmHg/min, p = 0.356, for autoantibody-negative vs. 
autoantibody-positive, respectively; Fig. 2).
Additionally, we compared the adjusted mean FVC 
changes between autoantibody-positive patients 
treated with pirfenidone and those who were never 
treated with pirfenidone. FVC declined more signifi-
cantly in those who were never treated with pirfeni-
done than those treated with pirfenidone; the adjusted 
mean difference in FVC change between these groups 
was 169.7 mL (p = 0.031; Fig. 3).
Table 2 Positivity rate for each autoantibody
Values are expressed as number (%, n = number of patients in whom antibodies were evaluated)
ANA anti-nuclear antibody, ANCA anti-neutrophil cytoplasmic antibody, RF rheumatoid factor
Total (n = 234) Patients treated with pirfenidone 
(n = 142)
Patients never treated 
with pirfenidone 
(n = 92)
ANA 42 (17.9%, n = 234) 27 (19.0%, n = 142) 15 (16.3%, n = 92)
RF 33 (14.4%, n = 229) 23 (16.8%, n = 137) 10 (10.9%, n = 92)
Cyclic citrullinated peptide antibody 8 (3.7%, n = 214) 7 (5.7%, n = 123) 1(1.1%, n = 91)
Anti-dsDNA antibody 3 (2.6%, n = 117) 3 (4.0%, n = 75) 0 (0.0%, n = 42)
Anti-Ro antibody 8 (6.6%, n = 121) 4 (5.1%, n = 79) 4 (9.5%, n = 42)
Anti-La antibody 0 (0.0%, n = 121) 0 (0.0%, n = 79) 0 (0.0%, n = 42)
Anti-ribonucleoprotein antibody 1 (0.9%, n = 110) 1 (1.4%, n = 71) 0 (0.0%, n = 39)
Anti-Smith antibody 2 (1.8%, n = 110) 0 (0.0%, n = 71) 2 (5.1%, n = 39)
Anti-Scl-70 antibody 4 (3.7%, n = 109) 0 (0.0%, n = 70) 4 (10.3%, n = 39)
Anti-Jo-1 antibody 3 (3.0%, n = 99) 2 (3.3%, n = 60) 1 (2.6%, n = 39)
Myeloperoxidase ANCA 31 (13.4%, n = 231) 14 (10.1%, n = 139) 17(18.5%, n = 92)
Proteinase-3 ANCA 7 (3.0%, n = 230) 6 (4.3%, n = 138) 1(1.1%, n = 92)





































Overall p-value = 0.356
Autoantibody (+)
Autoantibody (-)
Baseline 6 months 12 months
a
b
Fig. 2 Changes in FVC and  DLCO according to the autoantibody status. a No difference in the change in FVC between the autoantibody-negative 
and autoantibody-positive groups (p = 0.168); b No difference in the change in  DLCO between the autoantibody-negative and 
autoantibody-positive groups (p = 0.356).  DLCO, diffusing capacity of the lungs for carbon monoxide; FVC forced vital capacity
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Discussion
In this retrospective observational study, we show a simi-
lar slowing effect of pirfenidone on the progression of IPF 
irrespective of the autoantibody status. A similar change 
in FVC was found in autoantibody-positive and autoan-
tibody-negative patients with IPF. The change in FVC 
among autoantibody-positive patients treated with pirfe-
nidone was smaller than in those who were never treated 
with it. Therefore, we conclude that pirfenidone has simi-
lar efficacy in attenuating the FVC decline in patients 
with IPF irrespective of the autoantibody status.
Several studies have reported on the role of autoim-
munity in the pathogenesis of IPF. Activated T cells, 
including autoreactive CD4 T cells, were found in the 
blood, lung tissues, hilar lymph nodes, and bronchoal-
veolar lavage fluid of patients with IPF [18, 19]. It was 
demonstrated that T cells assist B cells in proliferat-
ing and producing autoantibodies, and that this process 
facilitates inflammation and fibrosis in the lungs [20, 21]. 
However, the clinical implications of this experimentally 
proven evidence are uncertain.
The rate of autoantibody positivity in patients with IPF 
in this study was lower than that reported in other stud-
ies [12, 13, 22], but similar to that observed in healthy 
adults [6, 23]. This study was performed at a tertiary uni-
versity hospital with a medical team specialized in inter-
stitial lung diseases, and only respiratory specialists were 
authorized to prescribe pirfenidone. Patients diagnosed 
with IPF and prescribed pirfenidone were routinely fol-
lowed up by a respiratory specialist. Therefore, although 
the patients were initially diagnosed with IPF, the respira-
tory specialist routinely examined them for evidence of 
alternative diagnoses. Particularly, the autoantibody-pos-
itive patients were reevaluated for alternative diagnoses 
if autoimmune features were observed during follow-up. 
This might explain the low autoantibody-positive rate in 
patients with IPF in this study.
Recently, a study reported that autoantibody-positive 
patients with IPF had a better prognosis than those nega-
tive for autoantibodies; additionally, immunomodula-
tors, including steroids, had positive effects on mortality. 
The authors suggested that different treatment strategies 
should be enacted based on the presence of autoanti-
bodies [12]. However, even if the autoantibody-positive 
patients did not meet the autoimmune disease criteria 
at the time of IPF diagnosis, the close follow-up of true 
patients with IPF to detect autoimmune diseases dem-
onstrated attenuation of FVC decline due to pirfenidone 
treatment, an effect that was observed regardless of the 
autoantibody status. Therefore, we suggest close moni-
toring of patients with IPF for alternative diagnoses when 
pirfenidone is ineffective, especially in autoantibody-pos-
itive patients, instead of attempting different treatment 
strategies based on the autoantibody status.
This study has several limitations. First, not all autoan-
tibodies in the IPAF serologic domain were tested in all 
patients. Therefore, patients included in the autoanti-
body-negative group may have actually been autoanti-
body-positive but were not tested for it. Second, masking 
of the differential effects of pirfenidone due to systemic 
corticosteroid use cannot be excluded. The proportion of 
patients using systemic corticosteroids for over 30  days 
was higher, and the duration of use was longer in the 
autoantibody-positive group than in the autoantibody-
negative group. Although the differences were statisti-
cally insignificant, the efficacy difference between the 
groups could have been masked by the longer and higher 
systemic corticosteroid use in the autoantibody-positive 
group. Third, nintedanib, which is another anti-fibrotic 
approved for the treatment of IPF, was not covered by 
Korean health insurance until recently [24]. As a result, 
we were unable to evaluate the impact of autoantibody 
status on the efficacy of this treatment in our patient 
population due to small numbers of patients on this 
medication. Finally, as a single center study, the result of 
our study requires replication in larger and more diverse 
patient cohorts to be generalized.
Conclusions
The patients in this study were diagnosed with IPF after 
excluding other possible diagnoses. We found that pirfe-
nidone slowed the progression of IPF, independent of the 
autoantibody status. We suggest that patients with IPF 
who do not respond to pirfenidone should be reevaluated 
for underlying autoimmune diseases.
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Overall p-value = 0.031
Autoantibody (+), pirfenidone (-)
Autoantibody (+), pirfenidone (+)
6 months 12 monthsBaseline
Fig. 3 FVC changes in autoantibody-positive patients in relation 
to pirfenidone treatment. FVC declined in patients who were never 
treated with pirfenidone more than in those treated with pirfenidone 
(p = 0.031). FVC forced vital capacity
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